Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued
Reference number: GID-TA10327
The Department for Health and Social Care has asked NICE to conduct an appraisal of veliparib in combination for treating BRCA-positive, HER2-negative, breast cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during mid-August 2020 when we will write to you about how you can get involved.